BioVie Inc.

3.43+0.0124+0.36%Vol 171.89K1Y Perf 40.74%
Oct 3rd, 2023 15:51 DELAYED
BID3.41 ASK3.44
Open3.32 Previous Close3.42
Pre-Market3.47 After-Market-
 0.05 1.46%  - -
Target Price
9.75 
Analyst Rating
Strong Buy 1.00
Potential %
184.26 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
9.06 
Earnings Rating
Market Cap126.33M 
Earnings Date
3rd Nov 2023
Alpha0.02 Standard Deviation0.46
Beta1.71 

Today's Price Range

3.213.50

52W Range

2.3414.38

5 Year PE Ratio Range

-2.20-0.9000

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-3.12%
1 Month
10.68%
3 Months
-18.96%
6 Months
-53.15%
1 Year
40.74%
3 Years
-63.50%
5 Years
-60.91%
10 Years
-

TickerPriceChg.Chg.%
BIVI3.430.01240.36
AAPL172.36-1.3900-0.80
GOOG133.33-1.8400-1.36
MSFT313.13-8.6700-2.69
XOM115.770.14000.12
WFC38.61-1.0000-2.52
JNJ155.420.26500.17
FB196.640.99000.51
GE107.79-1.0000-0.92
JPM142.80-0.9700-0.67
Financial StrengthValueIndustryS&P 500US Markets
5.20
5.30
0.68
2.15
-8.60
Leverage Ratio 4.50
ProfitabilityValueIndustryS&P 500US Markets
-
-
-
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q04 2023-0.37-0.2337.84
Q03 2023-0.31-0.43-38.71
Q01 2023--0.38-
Q03 2022-0.52-0.2846.15
Q02 2022-0.41-0.2246.34
Q02 2021-0.12-0.22-83.33
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date3rd Nov 2023
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume171.89K
Shares Outstanding36.80K
Shares Float13.17M
Trades Count1.53K
Dollar Volume581.06K
Avg. Volume255.98K
Avg. Weekly Volume294.48K
Avg. Monthly Volume262.98K
Avg. Quarterly Volume210.48K

BioVie Inc. (NASDAQ: BIVI) stock closed at 3.42 per share at the end of the most recent trading day (a 0.29% change compared to the prior day closing price) with a volume of 260.08K shares and market capitalization of 126.32M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 4 people. BioVie Inc. CEO is Terren S. Peizer.

The one-year performance of BioVie Inc. stock is 40.74%, while year-to-date (YTD) performance is -55.98%. BIVI stock has a five-year performance of -60.91%. Its 52-week range is between 2.3417 and 14.38, which gives BIVI stock a 52-week price range ratio of 9.06%

BioVie Inc. currently has a PE ratio of -5.00, a price-to-book (PB) ratio of 32.80, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -138.10%, a ROC of -107.24% and a ROE of -236.37%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from BioVie Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. BioVie Inc.’s next earnings report date is 03rd Nov 2023.

The consensus rating of Wall Street analysts for BioVie Inc. is Strong Buy (1), with a target price of $9.75, which is +184.26% compared to the current price. The earnings rating for BioVie Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioVie Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BioVie Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 25.16, ATR14 : 0.32, CCI20 : 69.04, Chaikin Money Flow : -0.18, MACD : -0.10, Money Flow Index : 39.91, ROC : -1.16, RSI : 51.68, STOCH (14,3) : 71.84, STOCH RSI : 0.90, UO : 51.98, Williams %R : -28.16), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioVie Inc. in the last 12-months were: Cuong Do (Sold 0 shares of value $0 ), Richard J. Berman (Sold 10 984 shares of value $93 581 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

BioVie Inc.

BioVie Inc is active in the healthcare domain in the United States. The company is a development stage enterprise engaged in the discovery, development, and commercialization of a therapy targeting ascites due to liver cirrhosis. Its therapy BIV201 is based on a drug that is approved in about 40 countries to treat related complications of liver cirrhosis. BioVie is developing BIV201 for alleviating the portal hypertension and correcting splanchnic vasodilation, thereby increasing effective blood volume and reducing the signals to the kidneys to retain excess salt and water.

CEO: Terren S. Peizer

Telephone: +1 312 283-5793

Address: 2120 Colorado Avenue, Santa Monica 90404, CA, US

Number of employees: 4

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

58%42%

Bearish Bullish

61%39%

 

News

Stocktwits